The MLLT11 overexpression induces tumorigenesis, development, and resistance in endometrial cancer by targeting the Akt protein and consequently inhibiting the PI3K/AKT/mTOR signaling pathway [106]. The gene discussed is AKT1; the disease is endometrial cancer.